OCALA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first new subject has been dosed in Phase 2 of the ...

"In the AIM acquisition model, the DoD and DHS agencies establish problem statements and invite non-traditional companies, acquisition subject matter experts, other government agency subject ...

npj Soft Matter is a dedicated home for publishing high-impact research that advances our understanding of soft matter systems. The journal aims to serve as a comprehensive platform for scientists ...

OCALA, Fla., July 10, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (AIM) (“AIM”) today announced it has enrolled and dosed the first subject in the company’s Phase 2 study evaluating ...

First enrollment takes place at Erasmus Medical Center in Rotterdam, Netherlands Erasmus Medical Center Erasmus Medical Center OCALA, Fla., Jan. 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc ...

Subject Matter Areas. AI and Advanced Tech. Airport & Aviation ... Air Force Weather-Funded Research Aims to Improve Predictability ... An area of climate research known as subseasonal to seasonal ...

Scientists develop 3D printed vacuum system that aims to trap dark matter. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2024 / 06 / 240617173515.htm ...

OCALA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first new subject has been dosed in Phase 2 of the ...

First enrollment takes place at Erasmus Medical Center in Rotterdam, Netherlands. OCALA, Fla., Jan. 22, 2024-- AIM ImmunoTech Inc. today announced that the first subject has been enrolled at ...

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19.

--AIM ImmunoTech Inc. today announced that the first subject has been enrolled at Erasmus Medical Center in a Phase 1 b/2 clinical trial combining AIM’ s Ampligen ® with AstraZeneca’ s anti ...